Medicus Pharma Ltd. Common Stock·Healthcare
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, confirming that it has submitted an optimized Phase 2 study design to the US Food and Drug Administration targeting acute urinary retention (AUR) relapse prevention. Speaking to Proactive, chief medical officer Dr Faisal Mehmud said the company is refining its clinical approach to improve both efficiency and speed of decision-making.
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, confirming that it has...
4.15pm: Deadline eyed US stocks finished the day on the front foot on hopes that a ceasefire deal will be reached between the US and Iran before Trump’s...
Boot Barn (NYSE:BOOT) has been upgraded to a ‘Buy’ rating from ‘Hold’ by Jefferies analysts, who cited a significant reset in valuation alongside resilient...
Bank of America shifted its rating on Carvana Co. (NYSE:CVNA) to Neutral on Monday, signaling a more cautious near-term outlook for the online used-car...
Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration (FDA) for Teverelix, an investigational GnRH antagonist. The study is designed to evaluate the drug's effectiveness in preventing recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of an existing open Investigational New Drug application.
